Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
11 oct. 2021 07h00 HE
|
Landos Biopharma, Inc.
Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage...
Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
06 oct. 2021 07h00 HE
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and...
Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)
27 sept. 2021 07h00 HE
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® advanced A.I. platform to develop...
Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai
20 sept. 2021 07h00 HE
|
Landos Biopharma, Inc.
Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney...
Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021
15 sept. 2021 07h00 HE
|
Landos Biopharma, Inc.
Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling Phase...
Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
01 sept. 2021 07h00 HE
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop...
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
26 août 2021 07h00 HE
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel...
Landos Biopharma to Participate in Upcoming Investor Events
05 août 2021 07h00 HE
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel...
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
29 juil. 2021 07h30 HE
|
Landos Biopharma, Inc.
Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC) Initiated...
Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021
22 juil. 2021 07h00 HE
|
Landos Biopharma, Inc.
Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients Following the recent positive End-of-Phase 2 meeting with the FDA,...